Future4care

🎤 What do startups say about Future4care's Go-to-Market Program? 👉 Today, hear from sleep2 - wake up like new. Founded in Austria in 2022, sleep² is a digital health company transforming the way people sleep. Medical device, sleep² combines cutting-edge sleep science with digital solutions for individuals, employers, insurers, researchers, and healthcare providers. From sleep analysis and coaching to health programs and lab-quality sleep data, sleep² empowers better sleep through evidence-based innovation. "It is very helpful to gain knowledge about the French healthcare system because it is quite complex. It is also very valuable to be introduced to relevant stakeholders, in our case insurance companies and hospitals." ☀️ There's still time to apply to our Go-to-Market Program! Applications for the third cohort are open until September 4. 🚀This unique, one-year program is designed to help international digital health startups understand, navigate, and validate their market entry strategy in France and Germany. 👉 Learn more and apply here: https://lnkd.in/efiDWNBx Dr. Thomas Winkler Katherine Ossenkopp Estefanía 'Nia' Escobar-Kölle Yannick Menel Albert Chevallier

🚀 Looking to grow your digital health startup in France and Germany? 🔊 Good news: applications for the third cohort of Future4care's Go-to-Market Program are now open until September 4. If you're planning to enter the French and German healthcare markets, this one-year, equity-free program will give you the tools, insights, and connections you need to build a successful market entry strategy. During the program, you will: ✨ Develop a tailored go-to-market strategy for France and Germany ✨ Better understand regulatory requirements, reimbursement models, and healthcare market dynamics ✨ Learn from industry experts and connect with leading stakeholders across the European HealthTech ecosystem ✨ Present your solution at Future4care's 2027 Demo Day in Paris with your own dedicated booth 🌍 Take the next step in your European expansion and join a community of ambitious international innovators. 📅 Applications close on September 4. Apply now: https://lnkd.in/efiDWNBx Yannick Menel Katherine Ossenkopp Estefanía 'Nia' Escobar-Kölle Albert Chevallier Romane Dorado Doncel

📢 Future4care's Go-to-Market Program: don't miss your chance to apply! 💥 Following strong interest from digital health startups around the world, we've extended the application deadline for the third cohort of Future4care's Go-to-Market Program until September 4. 👉 Are you ready to expand into France and Germany? Our unique one-year program is designed to help international digital health startups understand, navigate, and validate their market entry strategy in two of Europe's most strategic healthcare markets. Over the course of the program, you'll: ✅ Build and refine a market access strategy tailored to the French and German healthcare systems ✅ Gain a deeper understanding of reimbursement, regulatory pathways, and market-specific challenges ✅ Connect with leading industry experts and key players across Europe's HealthTech ecosystem ✅ Showcase your innovation with a dedicated booth at Future4care's 2027 Demo Day in Paris 🚀 Ready to accelerate your European expansion? Apply before September 4: https://lnkd.in/efiDWNBx

🧬 TechBio is rewriting the rules of drug discovery and is rapidly gaining momentum in Europe. The TechBio Commission (WhiteLab Genomics, Future4care, France Biotech, France Deeptech, Scienta Lab) is featured in Maddyness, with insights from our Global Head of Business Development & Licensing, Timothé CYNOBER. Distinct from biotech by nature, TechBio stands at the intersection of biology, data, and AI. TechBio makes it possible to explore massive sets of biological data and uncover the mechanisms behind diseases, accelerating the identification of new therapeutic targets and biomarkers, and improving clinical trials. 🚀 The ambition of the sector is to transform the way we develop drugs. We’re in the midst of organizing TechBio Europe, which is happening on November 30 at Future4Care. There will be exciting new additions to the 2026 program. More details to come! Check out the Maddyness TechBio article here 👉 https://lnkd.in/e2r5KjhV #techbio #frenchtech #deeptech #genomicmedicine #aiforgood #drugdiscovery

🧬 TechBio is rewriting the rules of drug discovery and is rapidly gaining momentum in Europe. The TechBio Commission (WhiteLab Genomics, Future4care, France Biotech, France Deeptech, Scienta Lab) is featured in Maddyness, with insights from our Global Head of Business Development & Licensing, Timothé CYNOBER. Distinct from biotech by nature, TechBio stands at the intersection of biology, data, and AI. TechBio makes it possible to explore massive sets of biological data and uncover the mechanisms behind diseases, accelerating the identification of new therapeutic targets and biomarkers, and improving clinical trials. 🚀 The ambition of the sector is to transform the way we develop drugs. We’re in the midst of organizing TechBio Europe, which is happening on November 30 at Future4Care. There will be exciting new additions to the 2026 program. More details to come! Check out the Maddyness TechBio article here 👉 https://lnkd.in/e2r5KjhV #techbio #frenchtech #deeptech #genomicmedicine #aiforgood #drugdiscovery

🚀 Une belle mise en lumière de la filière TechBio et de sa structuration sur le marché français par Maddyness. 💡 Découvrez dans cet article, à travers les regards d’experts de Romane Dorado Doncel (Future4care), Franck AUGE (Servier) et Timothé CYNOBER (WhiteLab Genomics), comment la catégorie TechBio, à la croisée des mondes entre biologie, traitement de données et intelligence artificielle, gagne en importance et peut jouer un rôle clé dans le développement de candidats-médicaments. La notion de collaboration entre startups et laboratoires pharmaceutiques prend tout son sens dans le domaine de la TechBio, et c’est précisément la mission de Future4care : fédérer les acteurs à la pointe de l’innovation. C’est notamment l’ambition de la Commission TechBio, dont la 3e édition se tiendra à l’automne prochain aux côtés de France Biotech et de France Deeptech . 👉 L'article est à découvrir ici: https://lnkd.in/e2r5KjhV

🧬 Comment la TechBio se structure progressivement en France ? À la croisée de la biologie, de la data et de l’IA, cette filière émergente s’organise pour accélérer le développement de nouveaux médicaments et renforcer l’innovation en santé. Pour Maddyness, Romane Dorado Doncel de Future4care, Franck AUGE de Servier et Timothé CYNOBER de WhiteLab Genomics reviennent sur les enjeux de cette dynamique : structuration de l'écosystème, accès aux données de santé, financement et collaboration entre startups, industriels et hôpitaux. 👇 À lire sur Maddyness : https://lnkd.in/e2r5KjhV - En partenariat avec Future4care

After HealthTech ecosystem dinners in Munich, London, Paris, and Barcelona last year, we were delighted to come back to Paris for another one, this time together with Future4care. We brought together a small group of investors, industry leaders, and founders for amazing food and even better conversations. It's nice to see that our Paris ecosystem dinners are always the ones that fill up first - a great sign of just how vibrant the ecosystem is here. A huge thank you to everyone who joined. With two portfolio companies and one of our biggest contributors to dealflow, Paris remains one of the most exciting HealthTech hubs for us, and we're keen to keep deepening our presence here. We can't wait for the next YZR ecosystem dinner. And if there is a city we haven't been to yet but should, let us know! 🙏 Neyla Merheb | Amine Benmoussa | Maciek (Matt) Malenda | Yannick Menel | Baudouin Hue | Pius S. Hornstein, MSc, PhD | Gaston Vasseur | Rakia JAZIRI, Ph.D | Pierre Antoine Andre | Markus Feuerecker | Christina Schmidt

🎤 Pitch spotlight: discover Ariana Pharma, the startup reimagining drug development with Explainable AI. 💊With nearly 95% of drug candidates failing between Phase I and Phase III, improving clinical trial success has become one of the biggest challenges in healthcare innovation. 👉 Ariana Pharma is tackling this issue with its KEM® Explainable Artificial Intelligence (eXp.AI) platform, designed to analyze Phase I and Phase II clinical data and generate actionable insights. By leveraging Explainable AI, Ariana helps its partners design more effective, personalized clinical trials by identifying: 🔹 the most relevant clinical endpoints, 🔹 the patients most likely to respond to treatment, 🔹 and the most promising drug combinations. Watch their pitch to discover how Ariana Pharma is helping reshape the future of drug development. Thomas TURCAT